Аннотация:
Objective. To carry out a systematic analysis of the data available in modern Russian and foreign literature on the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents, such as Ovipol Clio. Material and methods. The review includes the data of foreign and Russian articles published in the past 10 years and found in the Pubmed on this topic. Particular attention is given to the 2015-2017 articles. Results. The paper describes the evidence base of the efficiency and safety of estriol-containing intravaginal drugs, such as Ovipol Clio, in the treatment of menopausal syndrome. Analyzing the literature has clearly shown that the use of Ovipol Clio causes a significant reduction in menopausal symptoms and an improvement of a woman’s urogenital health. In this case, the earlier the treatment is initiated after the onset of menopause, the lower risk of menopause-associated pathological conditions. Conclusion. Additional studies on the safety and efficiency of tran
Чилова Р. А. Раиса Алексеевна 1965-
Чушков Ю. В. Юрий Васильевич 1971-
Проклова Г. Ф. Гузель Фаритовна 1983-
Chilova R. A. Raisa Alekseevna 1965-
Chushkov Yu. V. Yurij Vasilyevich 1971-
Proklova G. F. Guzel` Faritovna 1983-
The evidence base of the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents
Текст визуальный непосредственный
Акушерство и гинекология
Бионика Медиа
Вып. 12 С. 126-130
2017
Статья
Hormone replacement therapy Menopausal syndrome Menopause Ovipol Clio
Objective. To carry out a systematic analysis of the data available in modern Russian and foreign literature on the efficiency of treatment for menopausal syndrome with intravaginal hormonal agents, such as Ovipol Clio. Material and methods. The review includes the data of foreign and Russian articles published in the past 10 years and found in the Pubmed on this topic. Particular attention is given to the 2015-2017 articles. Results. The paper describes the evidence base of the efficiency and safety of estriol-containing intravaginal drugs, such as Ovipol Clio, in the treatment of menopausal syndrome. Analyzing the literature has clearly shown that the use of Ovipol Clio causes a significant reduction in menopausal symptoms and an improvement of a woman’s urogenital health. In this case, the earlier the treatment is initiated after the onset of menopause, the lower risk of menopause-associated pathological conditions. Conclusion. Additional studies on the safety and efficiency of tran